Have multiple conditions? Click here

New Clinical Trials for Breast Cancer

The high visibility of breast cancer through things like the pink ribbon campaigns and breast cancer awareness month has resulted in a lot of focus on developing treatments for breast cancer. Breast cancer clinical research has improved treatments over the past few decades. These treatments are continually being tested and reviewed. There is still a large need for breast cancer clinical studies
 
If you are a survivor of breast cancer or are currently dealing with breast cancer, you may be eligible to take part in one of a current breast cancer clinical trial. Please review the list and contact us if you are interested. As always, participation in clinical trials is at no cost to you.
 

What is Breast Cancer?

Breast cancer occurs when cancer cells form in either the milk ducts or lobules of breast tissue. It is the most common non-skin cancer found in women and accounts for approximately 10% of all cancer in women. Breast cancer is classified by stages. Stage 0 is the earliest and most easily treated stage while stage 4 is the most advanced and dangerous stage. Breast cancer is often first detected when a woman feels a lump in her breast. She may also notice changes in the look, feel or color of her breasts. Frequent mammograms also often find the first signs of breast cancer. Factors that affect someone’s chances of developing breast cancer include sex, age, hormones, race, diet, and exercise.
 

Breast Cancer Treatments

Breast cancer treatments most often include a combination of surgery, drugs (hormonal and chemotherapy) and radiation. Surgery removes most of the cancer while radiation kills surrounding cells that may have been missed during surgery. Higher risk breast cancers include those that have spread to the lymph nodes in the armpits. These are treated with cyclophosphamide plus doxorubinin (CA). This treatment is effective, but has bad side effects because it also causes damage to normal cells. Hormone blocking therapy is another treatment for breast cancer. This blocks the estrogen that some cancers need to grow.

Have multiple conditions? Click here

Showing 1-100 of 8879
There are 8879 Breast Cancer Clinical Trials
Name City State Zip
Breast Cancer Clinical Trial Birmingham AL 35216
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer Mobile AL 36604
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer Mobile AL 36685
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases Mobile AL 36608
Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer Mobile AL 36608
A Phase I/II Clinical Trial of Vidaza With Abraxane in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer Mobile AL 36607
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Mobile AL 36608
Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer Mobile AL 36608
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement Mobile AL 36608
Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases Mobile AL 36608
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer Mobile AL 36604
Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer Mobile AL 36604
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer Mobile AL 36685
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Mobile AL 36608
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Mobile AL 36608
Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer Mobile AL 36604
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer Huntsville AL 35805
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer Huntsville AL 35805
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer Huntsville AL 35805
Magnetic Resonance Imaging in Women Receiving Chemotherapy for Stage III Breast Cancer Birmingham AL 35294
Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer Birmingham AL 35294
Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer Birmingham AL 35294
Lynne Cohen Consortium Project: Multi-Center Database/Registry Birmingham AL 35233
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer Birmingham AL 35235
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer Birmingham AL 35209
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer Birmingham AL 35213
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer Birmingham AL 35211
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer Birmingham AL 35294
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer Birmingham AL 35233
Investigation of Genetic Determinants of Capecitabine Toxicity Birmingham AL 35429
Collecting Information From Patients Enrolled in the Breast Specialized Program of Research Excellence Birmingham AL 35294
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer Birmingham AL
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) Birmingham AL
Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome Birmingham AL 35205
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes Birmingham AL 35294
Reducing Breast Cancer Recurrence With Weight Loss Birmingham AL 35233
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer Birmingham AL 35294
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2 Overexpressing Metastatic Breast Cancer Patients Birmingham AL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients Birmingham AL 35205
Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer Birmingham AL 35216
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer Birmingham AL 35294
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis Birmingham AL 35233
RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer Birmingham AL 35294
PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer Birmingham AL 35294
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer Bessemer AL 35022
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer Anniston AL 36207
Treatment Decision Making Based on Blood Levels of Tumor Cells in Women With Metastatic Breast Cancer Receiving Chemotherapy Anniston AL 36207
Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer Anniston AL 36207
Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer Alabaster AL 35007
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer Alabaster AL 35007
Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer Alabaster AL 35007
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Fairbanks AK 99701
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement Fairbanks AK 99701
Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases Fairbanks AK 99701
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Fairbanks AK 99701
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer Anchorage AK 99508
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer Anchorage AK 99508
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer Anchorage AK 99508
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer Anchorage AK 99508
Treatment Decision Making Based on Blood Levels of Tumor Cells in Women With Metastatic Breast Cancer Receiving Chemotherapy Anchorage AK 99508
Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer Anchorage AK 99508
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer Anchorage AK 99508
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer Anchorage AK 99508
Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases Anchorage AK 99508
Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer Anchorage AK 99508
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor Tucson AZ 85704
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Tucson AZ 85704
Paclitaxel and Trastuzumab and/or Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery Tucson AZ 85724
Breast Cancers: Risk Factors Among Mexican Women in Mexico, Mexican-American and African-American Women in the U.S. Tucson AZ 85724
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement Tucson AZ 85723
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer Tucson AZ 85745
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer Tucson AZ 85715
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer Tucson AZ 85704
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer Tucson AZ 85712
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer Tucson AZ 85710
Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer Tucson AZ 85724
Multidrug Resistance Proteins in Patients Enrolled in Clinical Trials Outside of the National Cancer Institute Center for Cancer Research Tucson AZ 85715
Studying Blood Samples in Women With Breast Cancer or a History of Breast Cancer Tucson AZ 85724
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer Tucson AZ 85724
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer Tucson AZ 85704
I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Tucson AZ 85721
Limonene Study in Women With Breast Cancer Tucson AZ 85724
Ixabepilone + Carboplatin Metastatic Breast Cancer Tucson AZ 85704
Letrozole in Treating Healthy Postmenopausal Women at High Risk for Breast Cancer Tucson AZ 85724
Comprehensive Patient Reported Outcomes (PRO) Management for Oncology Practice Tucson AZ 85724
Clinical Evaluation of OSNA Breast Cancer System in Breast Cancer Patients Receiving Neoadjuvant Therapy Tucson AZ 85724
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer Tucson AZ 85724
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors Tucson AZ 85724
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor Sedona AZ 86336
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer Sedona AZ 86336
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer Sedona AZ 86336
Ixabepilone + Carboplatin Metastatic Breast Cancer Sedona AZ 86336
Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer Scottsdale AZ 85258
Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer Scottsdale AZ 85259
Safety Study of Bevacizumab to Treat Women With a History of Breast Cancer and Suffering From Upper Extremity Lymphedema Scottsdale AZ 85260
Chemotherapy and Bevacizumab in Treating Women With Invasive Breast Cancer Scottsdale AZ 85258
Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study Scottsdale AZ 85258
Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer Scottsdale AZ 85259
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Scottsdale AZ 85258
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Scottsdale AZ 85260

Showing 1-100 of 8879
Alabama - Alaska - Arizona - Arkansas - California - Colorado - Connecticut - Delaware - Washington DC - Florida - Georgia - Hawaii - Idaho - Illinois - Indiana - Iowa - Kansas - Kentucky - Louisiana - Maine - Maryland - Massachusetts - Michigan - Minnesota - Mississippi - Missouri - Montana - Nebraska - Nevada - New Hampshire - New Jersey - New Mexico - New York - North Carolina - North Dakota - Ohio - Oklahoma - Oregon - Pennsylvania - Rhode Island - South Carolina - South Dakota - Tennessee - Texas - Utah - Vermont - Virginia - Washington - West Virginia - Wisconsin - Wyoming
For Sponsors: Promote Your Study | For Research Sites: Promote Your Site

Copyright 2012 Clinical Trials Institute, LLC | All Rights Reserved
Login
Forgot password?
Enter your email and we will resend your password
Register